Comprehensive Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034

What combination of drivers is leading to accelerated growth in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
The growing prevalence of chronic diseases is anticipated to drive the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic diseases are long-term conditions that develop gradually and persist for extended periods, often requiring ongoing medical attention. The increase in chronic diseases is linked to factors such as aging populations, sedentary lifestyles, poor diets, rising obesity rates, and exposure to environmental pollutants. ATTR-CM treatment aids by stabilizing transthyretin, reducing amyloid accumulation, enhancing heart function, and alleviating symptoms to better manage associated chronic conditions. For example, in September 2023, the World Health Organization reported that chronic diseases accounted for 74% of all deaths globally, with 41 million deaths annually. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the increasing prevalence of chronic diseases is driving the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Get Your Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

What is the projected compound annual growth rate (CAGR) of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market from 2025 to 2034, and what factors influence it?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market has expanded exponentially, growing from $10.36 billion in 2024 to $13.32 billion in 2025 at a CAGR of 28.5%. Factors contributing to this growth include the rising prevalence of ATTR-CM, an increasing geriatric patient population, heightened awareness among healthcare professionals and patients, and improvements in healthcare services.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to experience exponential growth, reaching $35.93 billion by 2029, with a CAGR of 28.2%. The rapid growth will be driven by an increasing prevalence of transthyretin amyloidosis, improved diagnosis of neuropathic disorders, a growing aging population, rising demand for targeted drugs to manage symptoms of this rare condition, and increasing demand for healthcare services. Major trends anticipated include advancements in diagnostic technologies, the development of innovative therapy management techniques, the introduction of targeted treatments for transthyretin amyloidosis, improvements in diagnostic methods, and the adoption of cardiac MRI techniques.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

How are the latest trends influencing the growth of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
In the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, companies are developing oral medications to target and stabilize transthyretin proteins or reduce amyloid fibril buildup in the heart. For example, in November 2024, BridgeBio Pharma received FDA approval for Attruby (acoramidis), an oral medication that stabilizes the transthyretin protein and reduces heart-related complications from ATTR-CM, showing rapid benefits for patients.

What are the major segments of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market and their role in driving growth?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented -

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

Which regions are key players in the growth of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

What Is Covered In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report?

•Market Size Forecast: Examine the transthyretin amyloid cardiomyopathy (attr-cm) treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the transthyretin amyloid cardiomyopathy (attr-cm) treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the transthyretin amyloid cardiomyopathy (attr-cm) treatment market.
•Competitive Landscape: Review strategic developments in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.